Duloxetine Hydrochloride Capsule, Delayed Release
Product Images NDC 46708-278

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine Hydrochloride (NDC 46708-278). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine-20mg.jpg (Duloxetine 20mg)

Label for Duloxetine Delayed-release Capsules USP, 20 mg, showing a capsule image with imprint "A 156". The label includes dosing warnings, storage instructions, manufacturer Alembic Pharmaceuticals Limited, and a count of 30 capsules per container. The NDC code 46708-278-30 is displayed along with a barcode and a pharmacist dispensing note.*

FDA Label Image

Duloxetine-30mg.jpg (Duloxetine 30mg)

Label for Duloxetine Delayed-release Capsules USP, 30 mg, manufactured by Alembic Pharmaceuticals Limited. The label includes NDC 46708-279-30, directions for dispensing, storage instructions, and a capsule image showing blue and white colors with imprint '157'. The package contains 30 capsules and is labeled for pharmacist dispensing with Rx only.*

FDA Label Image

Duloxetine-60mg.jpg (Duloxetine 60mg)

Label for Duloxetine delayed-release capsules USP 60 mg by Alembic Pharmaceuticals Limited. The label states each capsule contains 67.3 mg duloxetine hydrochloride USP equivalent to 60 mg duloxetine, includes storage instructions, and a warning about the inner seal. The package contains 30 capsules for oral use, prescription only. The label features the NDC 46708-280-30 and Alembic's logo.*

FDA Label Image

Duloxetine Fig1

A line graph depicting the proportion of patients with relapse over time in days from randomization, comparing two treatments: Placebo and Duloxetine. The x-axis represents time from randomization to relapse (in days), and the y-axis shows the proportion of patients with relapse. The graph includes two curves, one for placebo and one for duloxetine, illustrating their relapse rates over approximately 200 days.*

FDA Label Image

Duloxetine Fig10

A line graph comparing the percentage of patients improved in pain from baseline between placebo and Duloxetine 60/120 mg once daily. The x-axis represents the percent improvement in pain from baseline, while the y-axis shows the percentage of patients improved. The graph features two lines: one dashed for placebo and one solid for Duloxetine, illustrating patient response across various improvement thresholds.*

FDA Label Image

Figure 2 (Duloxetine Fig2)

A line graph showing the proportion of patients with relapse over time (days) from randomization. The graph compares two treatments: placebo, represented by a dashed line, and duloxetine, represented by a solid line. The x-axis shows time from 0 to 300 days, and the y-axis shows the proportion of patients with relapse from 0 to 1.*

FDA Label Image

Duloxetine Fig3

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The graph compares the effectiveness of different Duloxetine doses in improving patient pain levels.*

FDA Label Image

Duloxetine Fig4

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups. The x-axis represents percent improvement in pain from baseline (0% to 100%), and the y-axis shows the percentage of patients improved (0% to 100%). Three lines show patient response differences between the dosing regimens and placebo over varying pain improvement thresholds.*

FDA Label Image

Duloxetine Fig5

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, illustrating patient response rates across different pain improvement thresholds.*

FDA Label Image

Duloxetine Fig6

A line graph depicting the percentage of patients improved relative to percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo. Each group's percentage of patients improved decreases as the percent improvement in pain increases, with placebo consistently showing the lowest improvement rates.*

FDA Label Image

Duloxetine Fig8

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline, comparing Placebo and Duloxetine 60/120 mg once daily. The graph plots percent improvement on the x-axis and percentage of patients improved on the y-axis, illustrating treatment efficacy differences.*

FDA Label Image

Duloxetine Fig9

A line graph comparing the percentage of patients improved between placebo and duloxetine 60 mg once daily. The x-axis represents percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved. Two lines illustrate that duloxetine generally results in higher patient improvement percentages across various pain improvement thresholds compared to placebo.*

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure diagram of duloxetine hydrochloride, the active ingredient in DULOXETINE HYDROCHLORIDE delayed-release capsules by Alembic Pharmaceuticals Limited. The structure includes a naphthalene moiety, a thiophene ring, and an amine group with hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.